ANKRD35 Activators
ANKRD35 activators encompass a diverse range of chemical compounds that indirectly enhance its functional activity through modulation of various signaling pathways. Forskolin, for example, by elevating intracellular cAMP levels, indirectly augments ANKRD35's activity by activating PKA, which influences substrates in pathways involving ANKRD35. Similarly, LY294002, as a PI3K inhibitor, and Wortmannin, diminish PI3K/AKT pathway signaling, potentially enhancing ANKRD35's role in alternate signaling pathways. Inhibition of MEK1/2 by U0126 and MEK1 by PD98059 shifts cellular signaling towards pathways that involve ANKRD35, thereby potentially enhancing its function. Genistein, by inhibiting tyrosine kinase activity, may also increase the functional role of ANKRD35 by reducing competition in related signaling pathways.
Furthermore, the functional dynamics of ANKRD35 are influenced by other specific inhibitors like SB203580, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor. These inhibitors potentially shift the signaling equilibrium in favor of pathways where ANKRD35 is involved, thus enhancing its activity. Sunitinib, as a receptor tyrosine kinase inhibitor, and Rapamycin, an mTOR inhibitor, also contribute to the modulation of ANKRD35's activity by altering the dominance of specific pathways. Dorsomorphin, by targeting BMP signaling, and AICAR, through AMPK activation, further influence the functional landscape of ANKRD35. These compounds, by modulating key regulatory pathways, enhance the involvement and activity of ANKRD35 in various cellular processes. Collectively, these activators of ANKRD35, through their targeted effects on cellular signaling, facilitate the enhancement of ANKRD35-mediated functions without necessitating direct activation or upregulation of its expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels. Elevated cAMP activates PKA, which can phosphorylate substrates involved in pathways where ANKRD35 is a component, thus indirectly enhancing ANKRD35's functional role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As a PI3K inhibitor, LY294002 diminishes PI3K/AKT pathway signaling. This reduction in PI3K/AKT pathway activity can lead to an enhanced activity of pathways where ANKRD35 is a critical component, indirectly increasing its functional role. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38, this compound can shift the signaling balance towards pathways involving ANKRD35, thereby indirectly enhancing its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, a key component of the MAPK/ERK pathway. This inhibition can lead to an increased activity of alternative signaling pathways where ANKRD35 plays a role, indirectly enhancing its functional role. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
As a tyrosine kinase inhibitor, Genistein reduces competitive tyrosine kinase signaling, which may enhance pathways where ANKRD35 is involved, thereby increasing its functional activity indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor, specifically blocking MEK1 activation. This inhibition can shift cellular signaling towards pathways involving ANKRD35, thus enhancing its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
This compound is a JNK inhibitor. By inhibiting JNK, SP600125 can lead to an enhanced activity of ANKRD35 in pathways where JNK signaling is usually competitive or regulatory. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. By inhibiting PI3K, it can lead to an enhanced role of ANKRD35 in cellular pathways where PI3K/AKT signaling is usually dominant or suppressive. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib, a receptor tyrosine kinase inhibitor, can reduce competitive signaling in pathways where ANKRD35 is a component, thereby indirectly enhancing ANKRD35's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, Rapamycin can enhance the functional role of ANKRD35 by shifting the cellular signaling balance towards pathways where ANKRD35 is involved. | ||||||